{"id":"dgd","safety":{"commonSideEffects":[{"rate":null,"effect":"Transient hyperemia/erythema at application site"},{"rate":null,"effect":"Mild pain or discomfort during debridement"},{"rate":null,"effect":"Bleeding or oozing from wound bed"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DGD (Desiccated Gamma-Irradiated Bromelain) is an enzymatic debridement agent derived from bromelain that targets and digests only dead, denatured tissue while preserving viable tissue. It works by enzymatically breaking down the extracellular matrix components in eschar and necrotic wound tissue, facilitating their removal without surgical intervention. This selective proteolytic action promotes faster wound healing and reduces the need for surgical debridement in severe burns.","oneSentence":"DGD is a recombinant protease that selectively debrides necrotic tissue by breaking down denatured collagen and proteins in burn wounds.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:19.992Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Enzymatic debridement of eschar in thermal burns"},{"name":"Removal of necrotic tissue in deep partial and full-thickness burn wounds"}]},"trialDetails":[{"nctId":"NCT00898521","phase":"PHASE2","title":"Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns","status":"COMPLETED","sponsor":"MediWound Ltd","startDate":"2009-12-20","conditions":"Burn","enrollment":36},{"nctId":"NCT00324311","phase":"PHASE3","title":"Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care","status":"COMPLETED","sponsor":"MediWound Ltd","startDate":"2005-12","conditions":"Burn","enrollment":182}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":314,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DGD","genericName":"DGD","companyName":"MediWound Ltd","companyId":"mediwound-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DGD is a recombinant protease that selectively debrides necrotic tissue by breaking down denatured collagen and proteins in burn wounds. Used for Enzymatic debridement of eschar in thermal burns, Removal of necrotic tissue in deep partial and full-thickness burn wounds.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}